Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Completed · Phase 2

Conditions studied: Thyroid Neoplasms

In brief

The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine

Key facts

Study ID

NCT00389441

Run by

Pfizer

People needed

52

Starts

2006-12-01

Expected to finish

2012-09-01

Last updated by the study team

2013-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer
• At least 1 measurable target lesion, as defined by RECIST

You may not qualify if…

• Thyroid lymphoma
• Previous treatment with anti-angiogenesis agents
• No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism within 12 months prior.

Where it is running

• Pfizer Investigational Site — Orange, California, United States
• Pfizer Investigational Site — Aurora, Colorado, United States
• Pfizer Investigational Site — Tampa, Florida, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Wichita, Kansas, United States
• Pfizer Investigational Site — Witchita, Kansas, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Buffalo, New York, United States
• Pfizer Investigational Site — Edmonton, Alberta, Canada
• Pfizer Investigational Site — London, Ontario, Canada
• Pfizer Investigational Site — Montreal, Quebec, Canada
• Pfizer Investigational Site — Nanjing, Jiangsu, China
• Pfizer Investigational Site — Beijing, China
• Pfizer Investigational Site — Shanghai, China
• Pfizer Investigational Site — Shanghai, China
• Pfizer Investigational Site — Prague, Czechia
• Pfizer Investigational Site — Vellore, Tamil Nadu, India
• Pfizer Investigational Site — Milan, Italy
• Pfizer Investigational Site — Pisa, Italy
• Pfizer Investigational Site — Gliwice, Poland
• Pfizer Investigational Site — Warsaw, Poland
• Pfizer Investigational Site — Madrid, Madrid, Spain
• Pfizer Investigational Site — Pamplona, Navarre, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.